Suppr超能文献

一位老友有多毒?羟氯喹在临床实践中的安全性综述。

How toxic is an old friend? A review of the safety of hydroxychloroquine in clinical practice.

机构信息

Department of Rheumatology, Royal Melbourne Hospital, Melbourne, Victoria, Australia.

Department of Medicine, The University of Melbourne at St Vincent's Hospital (Melbourne), Melbourne, Victoria, Australia.

出版信息

Intern Med J. 2023 Mar;53(3):311-317. doi: 10.1111/imj.15908. Epub 2022 Aug 25.

Abstract

Hydroxychloroquine (HCQ) and its close relative chloroquine (CQ) were initially used as antimalarial agents but are now widely prescribed in rheumatology, dermatology and immunology for the management of autoimmune diseases. HCQ is considered to have a better long-term safety profile than CQ and is therefore more commonly used. HCQ has a key role in the treatment of connective tissue diseases including systemic lupus erythematosus (SLE), where it provides beneficial immunomodulation without clinically significant immunosuppression. HCQ can also assist in managing inflammatory arthritis, including rheumatoid arthritis (RA). Debate around toxicity of HCQ in COVID-19 has challenged those who regularly prescribe HCQ to discuss its potential toxicities. Accordingly, we have reviewed the adverse effect profile of HCQ to provide guidance about this therapeutic agent in clinical practice.

摘要

羟氯喹(HCQ)及其近亲氯喹(CQ)最初被用作抗疟药物,但现在在风湿病学、皮肤病学和免疫学中被广泛用于治疗自身免疫性疾病。HCQ 被认为具有比 CQ 更好的长期安全性,因此更常用。HCQ 在治疗包括系统性红斑狼疮(SLE)在内的结缔组织疾病中具有重要作用,它提供有益的免疫调节而没有明显的临床免疫抑制作用。HCQ 还可以辅助治疗炎症性关节炎,包括类风湿关节炎(RA)。关于 COVID-19 中 HCQ 毒性的争论,使那些经常开具 HCQ 的医生不得不讨论其潜在毒性。因此,我们回顾了 HCQ 的不良影响谱,以提供有关该治疗药物在临床实践中的指导。

相似文献

1
How toxic is an old friend? A review of the safety of hydroxychloroquine in clinical practice.
Intern Med J. 2023 Mar;53(3):311-317. doi: 10.1111/imj.15908. Epub 2022 Aug 25.
4
Skin and ophthalmic complications of chloroquine and hydroxychloroquine in patients with rheumatoid arthritis and systemic lupus erythematous.
J Immunoassay Immunochem. 2024 May 3;45(3):178-188. doi: 10.1080/15321819.2024.2350544. Epub 2024 May 9.
5
American College of Rheumatology White Paper on Antimalarial Cardiac Toxicity.
Arthritis Rheumatol. 2021 Dec;73(12):2151-2160. doi: 10.1002/art.41934. Epub 2021 Oct 26.
6
Identification of new risk factors for hydroxychloroquine and chloroquine retinopathy in systemic lupus erythematosus patients.
Semin Arthritis Rheum. 2024 Jun;66:152417. doi: 10.1016/j.semarthrit.2024.152417. Epub 2024 Feb 12.
7
Hydroxychloroquine in systemic lupus erythematosus (SLE).
Expert Opin Drug Saf. 2017 Mar;16(3):411-419. doi: 10.1080/14740338.2017.1269168. Epub 2016 Dec 14.
8
Systemic toxicity of chloroquine and hydroxychloroquine: prevalence, mechanisms, risk factors, prognostic and screening possibilities.
Rheumatol Int. 2021 Jul;41(7):1189-1202. doi: 10.1007/s00296-021-04868-6. Epub 2021 Apr 24.
9
Chloroquine and hydroxychloroquine ototoxicity; potential implications for SARS-CoV-2 treatment. A brief review of the literature.
Am J Otolaryngol. 2021 Sep-Oct;42(5):102640. doi: 10.1016/j.amjoto.2020.102640. Epub 2020 Jul 8.
10
Long-term effectiveness of antimalarial drugs in rheumatic diseases.
Ann Rheum Dis. 1998 Oct;57(10):582-7. doi: 10.1136/ard.57.10.582.

引用本文的文献

2
Safety of Hydroxychloroquine: What a Dermatologist Should Know.
Am J Clin Dermatol. 2025 Mar;26(2):251-264. doi: 10.1007/s40257-025-00919-x. Epub 2025 Feb 3.
3
Late-onset Systemic Lupus Erythematosus.
Rheumatol Int. 2025 Jan 15;45(1):29. doi: 10.1007/s00296-024-05784-1.
4
Antimalarials in Lupus Nephritis: How Strong Is the Evidence?
Kidney360. 2024 Dec 1;5(12):1938-1947. doi: 10.34067/KID.0000000626. Epub 2024 Oct 21.
5
Treatment of Rheumatoid Arthritis Based on the Inherent Bioactivity of Black Phosphorus Nanosheets.
Aging Dis. 2024 Jun 3;16(3):1652-1673. doi: 10.14336/AD.2024.0319.
6
Utility of hydroxychloroquine laboratory monitoring in dermatologic and rheumatologic patients.
Arch Dermatol Res. 2024 May 22;316(5):194. doi: 10.1007/s00403-024-02876-7.
7
Management of Sjogren's Dry Eye Disease-Advances in Ocular Drug Delivery Offering a New Hope.
Pharmaceutics. 2022 Dec 31;15(1):147. doi: 10.3390/pharmaceutics15010147.

本文引用的文献

1
Hydroxychloroquine use is not associated with QTc length in a large cohort of SLE and RA patients.
Arthritis Res Ther. 2021 Oct 29;23(1):271. doi: 10.1186/s13075-021-02646-0.
2
Association of Higher Hydroxychloroquine Blood Levels With Reduced Thrombosis Risk in Systemic Lupus Erythematosus.
Arthritis Rheumatol. 2021 Jun;73(6):997-1004. doi: 10.1002/art.41621. Epub 2021 May 2.
3
Association of Hydroxychloroquine Use With Decreased Incident Atrial Fibrillation in Systemic Lupus Erythematosus.
Arthritis Care Res (Hoboken). 2021 Jun;73(6):828-832. doi: 10.1002/acr.24494.
4
Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID-19 Infection.
Clin Pharmacol Ther. 2020 Dec;108(6):1135-1149. doi: 10.1002/cpt.1993. Epub 2020 Sep 1.
5
Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive Mothers.
J Am Coll Cardiol. 2020 Jul 21;76(3):292-302. doi: 10.1016/j.jacc.2020.05.045.
7
Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection.
Circ Arrhythm Electrophysiol. 2020 Jun;13(6):e008662. doi: 10.1161/CIRCEP.120.008662. Epub 2020 Apr 29.
8
Understanding the dynamics of hydroxychloroquine blood levels in lupus nephritis.
Lupus. 2020 May;29(6):560-568. doi: 10.1177/0961203320912832. Epub 2020 Mar 19.
9
Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology.
Nat Rev Rheumatol. 2020 Mar;16(3):155-166. doi: 10.1038/s41584-020-0372-x. Epub 2020 Feb 7.
10
Hydroxychloroquine is associated with a lower risk of polyautoimmunity: data from the RELESSER Registry.
Rheumatology (Oxford). 2020 Aug 1;59(8):2043-2051. doi: 10.1093/rheumatology/kez562.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验